Tadalafil Offers Benefits for Benign Prostatic Hyperplasia

Treatment associated with relief from lower urinary tract symptoms, with infrequent adverse events

WEDNESDAY, Aug. 20 (HealthDay News) -- Daily treatment with tadalafil can relieve lower urinary tract symptoms in men with benign prostatic hyperplasia (BPH), according to research released online Aug. 19 in advance of publication in the October issue of the Journal of Urology.

Claus G. Roehrborn, M.D., of the University of Texas Southwestern Medical Center at Dallas, and colleagues analyzed data from 1,058 men, aged 45 and older, who were randomized to receive placebo or daily tadalafil at dosages of 2.5, 5, 10 or 20 milligrams for 12 weeks. All men had a history of lower urinary tract symptoms related to BPH for at least six months.

All dosages were associated with significant improvement in the International Prostate Symptom Score from baseline compared with placebo, the researchers report. The 5-mg dose provided additional improvements over the 2.5-mg dose, but the higher dosages provided minimal improvement, they note. The treatment was well-tolerated, and the 5-mg dose provided a positive risk-benefit profile.

"Although the precise mechanism of action by which PDE5 inhibitors may alleviate lower urinary tract symptoms is not completely understood, several putative mechanisms are currently under investigation. One mechanism focuses on the accumulation of intracellular prostatic and bladder smooth muscle cyclic guanosine monophosphate following PDE5 inhibition, which may decrease tension in the smooth muscle of the prostatic stroma and capsule. This muscle relaxation results in bladder neck opening and improved voiding function, and it decreases detrusor muscle overactivity in the bladder body and neck," the authors write.

The study was supported by Eli Lilly and Co.

Full Text

Physician's Briefing